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Glucagon levels are classically suppressed after glu-
cose challenge. It is still not clear as to whether a
lack of suppression contributes to hyperglycemia and
thus to the development of diabetes. We investigated
the association of postchallenge change in glucagon
during oral glucose tolerance tests (OGTTs), hypoth-
esizing that higher postchallenge glucagon levels are
observed in subjects with impaired glucose tolerance
(IGT). Glucagon levels were measured during OGTT
in a total of 4,194 individuals without diabetes in three
large European cohorts. Longitudinal changes in glu-
cagon suppression were investigated in 50 participants
undergoing a lifestyle intervention. Only 66–79% of
participants showed suppression of glucagon at 120 min
(fold change glucagon120/0 <1) during OGTT, whereas
21–34% presented with increasing glucagon levels
(fold change glucagon120/0 ‡1). Participants with non-
suppressed glucagon120 had a lower risk of IGT in all
cohorts (odds ratio 0.44–0.53, P < 0.01). They were also
leaner and more insulin sensitive and had lower liver
fat contents. In the longitudinal study, an increase
of fold change glucagon120/0 was associated with
an improvement in insulin sensitivity (P = 0.003). We
characterize nonsuppressed glucagon120 during the
OGTT. Lower glucagon suppression after oral glucose
administration is associated with a metabolically health-
ier phenotype, suggesting that it is not an adverse
phenomenon.
Under normal circumstances, glucagon levels are expected
to decline after oral glucose load. Rodent diabetes models
suggest that glucagon action is an important cause of
hyperglycemia (1). In humans, elevated fasting glucagon is
clearly associated with insulin resistance (2) and diabetes
(3). Important studies involving 20–31 participants showed
that a suppression of glucagon after an oral glucose load is
reduced in diabetes and impaired glucose tolerance (IGT)
(4–6). Thus, if glucagon made a causal contribution to di-
abetes pathogenesis, people with IGT would present with
only a slight suppression (or even an increase of glucagon)
during the oral glucose tolerance test (OGTT).
We therefore proposed that a reduced suppression of
glucagon during OGTT is associated with IGT. To test this
hypothesis, we analyzed cross-sectional data from three
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large European cohorts. All participants underwent stan-
dardized OGTTs. Two of the cohorts are enriched for
prediabetes. On the basis of previous data, in which a
sustained suppression of glucagon for up to 300 min after
oral glucose challenge (4–6) was observed, we compared
fasting glucagon with 2-h postchallenge glucagon lev-
els to determine glucagon suppression during OGTT.
We also studied the longitudinal changes of glucagon
suppression in a subgroup of individuals undertaking a
9-month lifestyle intervention.
RESEARCH DESIGN AND METHODS
Subjects
Tübingen Family Study and Tübingen Lifestyle
Intervention Program
Data were analyzed from subjects who had participated in
the Tübingen Family Study (TUEF) and the Tübingen
Lifestyle Intervention Program (TULIP). In TUEF, people
without diabetes with a family history of type 2 diabetes,
BMI .27 kg/m2, or a previous diagnosis of IGT under-
went metabolic phenotyping. Glucagon was originally mea-
sured in 625 subjects of the early TUEF cohort, 23 of
whom had incident diabetes. The latter were excluded
from the study. Clinical characteristics are given in Sup-
plementary Table 1.
TULIP was a standardized lifestyle intervention study
designed to identify predictors of metabolic changes over
9 months of moderate exercise and diet. In this project,
glucagon was measured during OGTTs in 50 subjects.
The study protocols were approved by the ethics
committee of the University of Tübingen. All participants
gave written informed consent.
Prevalence, Prediction and Prevention of Diabetes-
Botnia Study
The Prevalence, Prediction and Prevention of Diabetes
(PPP)-Botnia Study is a population-based study in the
Botnia region of Western Finland (7). It was designed
to obtain accurate estimates of prevalence and risk
factors for diabetes and prediabetes. The baseline study
was conducted from 2004 to 2008 in ﬁve Botnia cen-
ters comprising a total population of 135,000 people. In
total, 5,208 women and men participated (54.7% of those
invited). The participants gave their written informed con-
sent, and the study protocol was approved by the ethics
committee of Helsinki University Hospital.
Plasma glucagon was measured in participants recruited
after 2006. We excluded 98 subjects with incident
diabetes, and 1,369 had complete data sets for all inter-
mediary traits. Clinical details are given in Supplementary
Table 2.
Malmö Diet and Cancer Study
The study population consisted of those men and women
who had participated in the 2007–2012 (reexamination)
investigation of the cardiovascular cohort of the Malmö
Diet and Cancer Study (MDCS) (8,9). All participants in
the baseline study (n = 6,103) who were alive and who had
not emigrated from Sweden (n = 4,924) were invited to
the reexamination. A total of 3,734 subjects attended the
follow-up investigation (76% of the eligible population).
Of these, 2,371 had complete information for all analyzed
traits. A further 148 participants had since developed diabe-
tes and were therefore excluded from the analysis. All partic-
ipants provided written informed consent, and the study was
approved by the Lund University Ethics Review Committee.
Measurements
In all studies, subjects participated in a 75-g OGTT after
an overnight fast.
In TUEF and TULIP, blood samples were drawn after 0,
30, 60, 90, and 120 min. They were immediately put on
ice, centrifuged, and stored at280°C. The glucose-oxidase
method was used to determine plasma glucose (Yellow
Springs Instruments). Plasma insulin was determined
by chemiluminescence assays for ADVIA Centaur (Siemens
Medical Solutions).
In all studies, glucagon was collected in EDTA tubes
containing aprotinin and directly stored at 280°C (TUEF
and TULIP) or 220°C (MDCS and PPP-Botnia). In TUEF/
TULIP and PPP-Botnia, the samples were thawed only for
the glucagon assay after a mean lag of 6 months and
1.3 years. respectively, well before the actual analysis of
the data. For practical reasons, the analyses were per-
formed in MDCS and PPP-Botnia after all samples had
been collected. Glucagon was measured at fasting and
120 min in the data sets of all study centers. In TUEF,
glucagon was also measured after 30, 60, and 90 min
(n = 598, 447, and 446, respectively). We used the com-
mercially available radioimmunoassay (Linco Research/
Millipore, St. Charles, MO) (10). The analytical detection
limit was 5.3 pmol/L, and intra- and interassay coefﬁcients
of variation were ,6.8% and ,13.5%, respectively. Liver
fat was measured in 148 participants by MRS as previously
described (10).
In PPP-Botnia and MDCS, blood samples were obtained
after 0, 30, and 120 min. Plasma glucose was measured
using the glucose dehydrogenase method (Hemocue). Serum
insulin was measured by a ﬂuoroimmunometric assay
(AutoDELFIA; PerkinElmer) in PPP-Botnia and by ELISA
(Dako, Glostrup, Denmark) in MDCS.
Calculations and Statistics
Classiﬁcation of prediabetes was performed according to
American Diabetes Association criteria (normal glucose
tolerance [NGT], impaired fasting glycemia [IFG], and
IGT). The areas under the curve (AUCs) were calculated by
the trapezoid method (for glucagon using time points
0, 30, and 120; for other measures all ﬁve time points
in TUEF). The OGTT-derived insulin sensitivity index
(ISI-OGTT) was estimated as ISI-OGTT = 10,000=[(Glu0
$ Ins0 $ Glumean $ Insmean)]. Insulin secretion was assessed
by calculating the insulinogenic index [IGI = (insulin 30 2
insulin 0)/(glucose 30 2 glucose 0)].
1374 Postchallenge Glucagon Diabetes Volume 66, May 2017
Analytes determined at speciﬁc OGTT time points are
shown with the minutes of OGTT as subscript (e.g.,
glucagon120 for glucagon at the end of OGTT). Data are
shown as mean6 SD or median (interquartile range [IQR]).
The Wilcoxon rank sum/Kruskal-Wallis test was used to
compare continuous variables with nonnormal distribution.
Normally distributed variables were compared using Student
t test/ANOVA. Categorical variables were compared by x2
tests. Multivariable linear regression models or, in the event
of dichotomous outcomes, logistic models were used. Variables
Table 1—TUEF study: difference in metabolic traits during OGTT between the phenotypes with suppressed and nonsuppressed
glucagon
Suppressed glucagon120
during OGTT (n = 474)
Nonsuppressed glucagon120
during OGTT (n = 128)
P*
P† adjusted
for sex,
age, BMI
P† adjusted
for sex, age,
BMI, glucagon0Median/% IQR/95% CI Median/% IQR/95% CI
Sex (females) 62% (57–66)‡ 81% (74–87)‡ ,0.0001 NA NA
Age (years) 37.0 (30.0–49.0) 39.0 (31.0–48.0) 0.22 NA NA
BMI (kg/m2) 27.3 (23.7–32.7) 24.8 (22.4–28.3) ,0.0001 NA NA
Fasting glucose (mmol/L) 5.1 (4.8–5.4) 5.1 (4.8–5.3) 0.89 0.67 0.56
Glucose at 30 min (mmol/L) 8.4 (7.3–9.4) 8.1 (7.0–9.1) 0.04 0.24 0.86
Glucose at 60 min (mmol/L) 8.2 (6.7–9.9) 7.6 (5.9–8.9) 0.002 0.05 0.18
Glucose at 90 min (mmol/L) 6.9 (5.6–8.7) 5.9 (4.9–6.9) ,0.0001 ,0.0001 0.0003
Glucose at 120 min (mmol/L) 6.3 (5.3–7.6) 5.5 (4.8–6.3) ,0.0001 ,0.0001 ,0.0001
AUC glucose (mmol/L 3 120 min) 14.6 (12.6–16.8) 13.3 (11.8–15.3) ,0.0001 0.001 0.03
Fasting insulin (pmol/L) 50.0 (33.0–81.0) 38.0 (29.0–49.5) ,0.0001 0.002 0.08
Postchallenge insulin120 (pmol/L) 323.0 (183.8–607.3) 217.0 (143.0–342.5) ,0.0001 ,0.0001 0.002
AUC insulin (pmol/L 3 120 min) 380 (245–615) 274 (196–398) ,0.0001 0.003 0.09
Fasting glucagon (pmol/L) 19.2 (15.4–24.3) 14.2 (11.7–17.4) ,0.0001 ,0.0001 NA
Postchallenge glucagon120 (pmol/L) 14.5 (11.3–17.8) 16.8 (13.9–20.3) ,0.0001 ,0.0001 ,0.0001
AUC glucagon (pmol/L 3 120 min) 16.7 (13.4–20.6) 16.2 (13.4–19.8) 0.27 0.31 ,0.0001
ISI (OGTT derived, arbitrary units) 12.2 (7.6–20.8) 17.8 (13.4–25.8) ,0.0001 0.0003 0.03
Insulinogenic index (arbitrary units) 110.7 (69.1–182.9) 96.7 (60.7–164.5) 0.11 0.76 0.31
Hepatic fat content (%) (n = 148) 4.0 (1.8–10.2) 2.3 (1.2–3.7) 0.001 0.009 0.09
*Compared with the Wilcoxon rank sum test for nonnormally distributed variables and with Student t test for variables with normal distribution.
Binary outcomes were compared with x2 test; †in linear regression models or for binary outcomes, logistic models were adjusted for the given
covariates. Nonnormally distributed variables were log transformed prior to analysis; ‡data given are 95% CI. NA, not applicable.
Table 2—MDCS: difference in metabolic traits during OGTT between the phenotypes with suppressed and nonsuppressed
glucagon
Suppressed glucagon
during OGTT (n = 1,461)
Nonsuppressed glucagon
during OGTT (n = 762)
P†
P† adjusted
for sex,
age, BMI
P† adjusted
for sex, age,
BMI, glucagon0Median/% IQR Median/% IQR
Sex (females) 53% 75% ,0.0001 NA NA
Age (years) 72 (67–76) 73 (68–78) 0.006 NA NA
BMI (kg/m2) 26.5 (24.2–29.1) 25.3 (23.2–27.8) ,0.0001 NA NA
Fasting glucose (mmol/L) 5.8 (5.4–6.2) 5.7 (5.4–6.2) 0.002 0.40 0.6
Glucose at 120 min (mmol/L) 6.8 (5.6–8.2) 6.1 (5.0–7.3) ,0.0001 ,0.0001 ,0.0001
Fasting insulin (pmol/L) 56.9 (40.3–77.4) 42.4 (32.6–59.0) ,0.0001 ,0.0001 ,0.0001
Insulin at 30 min (pmol/L) 305.6 (211–435.5) 282.0 (201.4–404.3) 0.019 0.43 0.24
Insulin at 120 min (pmol/L) 291.0 (189.6–463.9) 219.8 (147.1–348.3) ,0.0001 ,0.0001 ,0.0001
Fasting glucagon (pmol/L) 22.7 (19.5–26.93) 18.9 (15.8–22.4) ,0.0001 ,0.0001 NA
Glucagon at 120 min (pmol/L) 19.2 (16.4–22.4) 21.8 (18.3–25.3) ,0.0001 ,0.0001 NA
ISI (OGTT derived, arbitrary units) 4.8 (3.1–7.2) 6.6 (4.4–10.1) ,0.0001 ,0.0001 ,0.0001
†In linear regression models or for binary outcomes, logistic models adjusted for the given covariates. Nonnormally distributed variables
were log transformed. NA, not applicable.
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with skewed distributions were loge transformed. The relative
change of glucagon from 0 to 120 min (glucagon120/
glucagon0) is referred to as fold change glucagon120/0
throughout the article. Calculations were performed with
JMP10 for TUEF and SPSS22 for PPP-Botnia and MDCS.
RESULTS
Cross-sectional Analysis
Fasting glucagon (glucagon0) was consistently higher in
subjects with IFG+IGT than in subjects with NGT (P ,
0.02). As anticipated, glucagon120 was lower than glucagon0
in all cohorts (P , 0.0001), indicating that a gross sup-
pression of glucagon occurs during OGTT. We calculated
the fold change of glucagon between fasting and 120 min
(fold change glucagon120/0), which had high variation in all
cohorts (TUEF: 0.84 6 0.25; PPP-Botnia: 0.87 6 0.24;
MDCS: 0.94 6 0.19). A substantial proportion of partici-
pants (21–34%) in all three cohorts had higher glucagon
120 min after glucose load (nonsuppressed glucagon120).
Contrary to our primary hypothesis, nonsuppressed
glucagon120 (fold change glucagon120/0 $1) was associ-
ated with a lower IGT risk (odds ratio [OR] 0.44–0.53
in all cohorts, P # 0.009); this remained essentially un-
changed after adjustment for sex, age, and BMI (OR 0.44–
0.47, P , 0.001). Further phenotypic differences between
subjects with suppressed and nonsuppressed glucagon in
TUEF and MDCS are shown in Tables 1 and 2. The ﬁve-
point OGTT course of glucagon, glucose, and insulin in
TUEF is shown in Fig. 1A–C. To enable us more clearly to
distinguish between participants with high and low fold
change glucagon120/0, we stratiﬁed subjects to decreasing, sta-
ble, and increasing glucagon (fold change glucagon120/0 ,0.9,
0.9–1.1, and .1.1, respectively) in the PPP-Botnia cohort
(Table 3). Irrespective of stratiﬁcation, participants with non-
suppressed or increasing glucagon120 were leaner and more
insulin sensitive in all cohorts, regardless of age, sex, or
BMI. To detect potential confounding by substantially
lower fasting glucagon levels in the nonsuppressed glu-
cagon120 subgroup, we additionally adjusted for fasting
glucagon. Nonsuppressed glucagon120 was still associated
with higher insulin sensitivity after adjustment for fasting
glucagon (TUEF: P = 0.03; MDCS: P , 0.0001).
Since glucagon may be a more important contributor of
postchallenge hyperglycemia at earlier time points of the
OGTT than glucagon120, we also investigated glucagon sup-
pression after 30, 60, and 90 min and its association with
IGT. Nonsuppressed glucagon30, glucagon60, and glucagon90
were seen in 40%, 27%, and 23% of subjects of the TUEF
cohort, but none were associated with IGT (OR 1.30, P =
0.31; OR 1.36, P = 0.32; OR 1.12, P = 0.72, respectively).
Glycemic data in TUEF and PPP-Botnia stratiﬁed by
prediabetes categories are shown in Supplementary Tables
1 and 2. Mean levels of glucose, glucagon, and insulin
during the ﬁve-point OGTT (Supplementary Table 4) with
an aggregated plot of relative glucagon courses (Supplemen-
tary Fig. 1) suggest that the lack of glucagon suppression
was not speciﬁc during the last 30 min of the OGTT. When
directly comparing glucagon suppression between NGT, IFG,
and IGT in the TUEF study at the intervals 0–30, 0–60,
0–90, and 0–120, only fold change glucagon120/0 was
different (Supplementary Table 5).
In PPP-Botnia, signiﬁcantly fewer of the 98 individuals
with incident diabetes had increasing or stable glucagon120
than subjects without diabetes (25 vs. 39%, P = 0.002).
Longitudinal Analysis
We also analyzed longitudinal data from the TULIP
intervention study (see Supplementary Table 3). We
Figure 1—Suppressed and nonsuppressed glucagon during OGTT.
Mean glucagon, glucose, and insulin levels per subphenotype (open
circles and continuous line represent subjects with suppressed glu-
cagon; closed triangles and dashed line represent subjects with
nonsuppressed glucagon) are shown in A, B, and C, respectively.
Error bars represent SEM.
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investigated whether individual change of fold change
glucagon120/0 is capable of predicting the change of ISI-
OGTT during lifestyle intervention. Increasing fold change
glucagon120/0 during the course of the lifestyle intervention
was signiﬁcantly associated with increasing ISI-OGTT after
appropriate adjustment for covariates (P = 0.003) (see Sup-
plementary Table 5).
DISCUSSION
Whereas a mixed-meal test elevates glucagon levels (11),
postprandial glucagon is expected to decline in subjects
without diabetes after oral pure glucose load (4–6). In a
smaller study, reduced glucagon suppression was found
to be associated with insulin resistance, IGT, and diabetes
(4). Thus, we hypothesized that nonsuppressed gluca-
gon after glucose challenge associates with postchallenge
hyperglycemia.
Glucagon120 was found not to be suppressed in 21–
34% of the 4,194 subjects who participated in the three
independent cohorts. Individuals with nonsuppressed glu-
cagon120 were consistently leaner and had a lower risk of
IGT and higher insulin sensitivity. In the subgroup under-
going MRS, these participants also had less liver fat than
those with the classic decrease in glucagon. Of note, subjects
with nonsuppressed glucagon120 had lower fasting glucagon
levels that potentially also contribute to the observed phe-
notype of nonsuppressed glucagon120. However, similar
AUC glucagon levels and additional controlling for fasting
glucagon suggested that fasting glucagon does not solely
explain the association between glucagon suppression and
insulin sensitivity. Thus, there appears to be an association
between nonsuppressed glucagon 2 h after glucose challenge
and a metabolically healthier phenotype that is not con-
nected with low fasting glucagon.
A recent investigation by Færch et al. (12) examining
glucagon levels in ;1,400 individuals at 0, 30, and 120 min
during an OGTT found lower early glucagon suppression
between minutes 0 and 30 and higher late glucagon sup-
pression between minutes 30 and 120 in subjects with pre-
diabetes and incident diabetes as compared with subjects
with NGT. Whereas our data on late glucagon suppression
(fold change120/0) are in accordance with this, the ﬁve-point
OGTT data in the TUEF cohort show a lack of a difference
for earlier time intervals in the OGTT between NGT and
prediabetes (30/0, 60/0, and 90/0) (Supplementary Table
5). In addition, the article by Færch et al. (12) showed
that higher insulin sensitivity was associated with higher
early glucagon suppression and lower late glucagon suppres-
sion. The latter is, again, corroborated by our data showing
higher insulin sensitivity in patients with higher fold
change glucagon120/0. In sum, these data suggest that the
insulin-sensitive and/or NGT phenotype is characterized by
a nonsuppression of glucagon120.
It has to be noted that glucagon levels were about
twofold higher in our study compared with the work of
Færch et al. (12). In contrast to the acknowledged proprie-
tary assay in the study by Færch et al., our measurements
were performed by a commercial assay in a multicenter
setting, and the data were consistent in all our cohorts.
Whether the association of nonsuppressed glucagon120
with NGT and higher insulin sensitivity is a physiologic mech-
anism pertaining to the prevention of late postprandial
hypoglycemia cannot be determined from our descrip-
tive studies.
However, it is intriguing to consider the potential
physiologic consequences of increasing glucagon levels
during the late OGTT. It has been shown that glucagon
action in the central nervous system leads to an inhibition
of hepatic glucose production, constraining the overshoot
of hyperglycemia after a surge of plasma glucagon (13).
Glucagon is an important satiety signal and enhances
adaptive thermogenesis (14). In our study, individuals with
nonsuppressed glucagon120 had a signiﬁcantly lower BMI.
Hepatic triglyceride content has a strong inverse association
with nonsuppressed glucagon120 in our data. The fact that
glucagon inhibits hepatic triglyceride synthesis and enhances
b-oxidation may raise the possibility that glucagon is pro-
tective against hepatic steatosis (15). Indeed, glucagon can
treat fatty liver in cows (16). Glucagon/GLP-1 coagonists are
under clinical development for the treatment of obesity and
diabetes (17). Sodium–glucose cotransporter 2 inhibitors
have been implicated in a direct stimulation of glucagon
secretion in the a-cell (18), and liraglutide induces a “para-
doxical” increase in postchallenge glucagon on chronic use
(19). Nonsuppressed glucagon could therefore contribute to
the beneﬁcial metabolic effects of these two drug classes.
The associations presented in our data do not allow
causal inference. A further limitation is that glucagon mea-
surement can be inﬂuenced by degradation and varying
assay speciﬁcity. However, a systematic bias is unlikely,
because samples were treated uniformly within studies
and the results are consistent in all investigated cohorts.
In summary, we characterize the increase of glucagon
from fasting to 120 min postchallenge as a phenomenon
associated with a desirable metabolic phenotype. These
data could provide an important context for the evolving
appreciation of glucagon’s multifaceted role in metabolism.
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